HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function.

AbstractBACKGROUND:
Atorvastatin and poly-unsaturated fatty acid (PUFA) are beneficial for lipid-modification, whether atorvastatin plus PUFA could confer better improvement on dyslipidemia and endothelium function is unknown.
METHODS:
Dyslipidemia model of 40 rabbits were produced with atherogenic diet, and thereafter saline, atorvastatin, PUFA, or atorvastatin plus PUFA were prescribed for 1 week. Ten rabbits given normal diet served as the sham group. Parameters of interest including lipid profiles, endothelium function (nitric oxide, NO) and activation (solution vascular-cellular adhesion molecule, (sVCAM) and intracellular adhesion molecule, (sICAM)), markers of inflammation (C-reactive protein, CRP) and oxidation (malondialdehyde, MDA) were compared among groups.
RESULTS:
There was no significant difference of parameters among groups at the initial. With 1 week of atherogenic diet administration, serum levels of lipid profiles, sVCAM and sICAM, CRP and MDA were significantly increased, accompanying with profound NO reduction, as compared to the sham group. After 1 week of medical intervention, as compared to the control group (saline administration), dyslipidemia and endothelium function were modestly improved with either atorvastatin or PUFA therapy. Nevertheless, these efficacies were further and significantly enhanced with combined therapy when compared to the control group (p<0.005), suggesting that there was synergistic effects of atorvastatin and PUFA co-therapy in rabbits with dyslipidemia.
CONCLUSION:
Atorvastatin plus PUFA therapy could immediately contribute to better improvement of lipid-modification and endothelium function in rabbits with dyslipidemia.
AuthorsXianbing Song, Hongsheng Liu, Xiaotian Wang, Zhenhua Li, Congwu Huang
JournalLipids in health and disease (Lipids Health Dis) Vol. 13 Pg. 186 (Dec 10 2014) ISSN: 1476-511X [Electronic] England
PMID25491404 (Publication Type: Journal Article)
Chemical References
  • Anticholesteremic Agents
  • Fatty Acids, Unsaturated
  • Heptanoic Acids
  • Pyrroles
  • Nitric Oxide
  • Atorvastatin
Topics
  • Animals
  • Anticholesteremic Agents (administration & dosage)
  • Atorvastatin
  • Drug Evaluation, Preclinical
  • Drug Therapy, Combination
  • Dyslipidemias (blood, drug therapy)
  • Endothelium, Vascular (drug effects, physiopathology)
  • Fatty Acids, Unsaturated (administration & dosage)
  • Heptanoic Acids (administration & dosage)
  • Male
  • Nitric Oxide (blood)
  • Pyrroles (administration & dosage)
  • Rabbits

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: